Close Menu

NEW YORK (GenomeWeb) – SEngine Precision Medicine said today that its Seattle-based laboratory has received CLIA certification.

The company's primary test offering, called PARIS, combines high-throughput drug screening of live, patient-derived tumor cells with DNA sequencing and data analysis to match individuals with optimal drug therapies.

SEngine said that its CLIA Laboratory now simultaneously screens up to 120 individual drugs and selected drug combinations.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to CNBC, Pfizer has announced that its SARS-CoV-2 vaccine data won't be ready this week.

A number of United Nations agencies push for scientific findings to be made accessible through open science.

Paris-Saclay University garners international regard following a decade-long effort to establish the new research university, Nature News reports.

In Nucleic Acids Research this week: database to house IndiGen sequencing data, database of SARS-CoV-2 docking scores, and more.